EU Science Hub

Skin sensitisation: the Direct Peptide Reactivity Assay (DPRA)

The direct peptide reactivity assay (DPRA) is used to contribute to the assessment of the skin sensitisation potential of chemicals.

The method models the covalent binding of a chemical to skin proteins (haptenation) which represents the first key event (KE1) of the skin sensitisation Adverse Outcome Pathway (AOP), also called Molecular Initiating Event (MIE), by quantifying the reactivity of chemicals towards synthetic peptides.

The DPRA was developed by Procter & Gamble in the US and has been evaluated in a EURL ECVAM coordinated validation study and subsequently underwent independent peer review by the EURL ECVAM Scientific Advisory Committee (ESAC).

The method is adopted by the OECD as TG 442C and by the EU as TM B59.

The results of the validation study, the peer review of ESAC and our recommendations can be found on TSAR, the Tracking System for Alternative methods towards Regulatory acceptance.

Read more about the Direct Peptide Reactivity Assay (DPRA) on TSAR

Skin sensitisation

The Direct Peptide Reactivity Assay (DPRA)

Animal testing replacement

Validation study

Validation study outcomes

EURL ECVAM recommendation